Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 6c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $340 thousand versus the consensus estimate of $532.75 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print
• UBS Reiterates Buy Rating on Darden Restaurants (DRI) Ahead of Q1 Earnings
• Palantir (PLTR) all put ratio 1.6 calls to 1 put with a focus on September 11 weekly 160 calls as share price up 1.4%